Estrella Immunopharma Inc. (ESLA) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Estrella Immunopharma Inc. (ESLA) has a cash flow conversion efficiency ratio of 1.271x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-6.70 Million) by net assets ($-5.27 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See net asset quality index of Estrella Immunopharma Inc. to measure how much of total assets are equity-financed.
Estrella Immunopharma Inc. - Cash Flow Conversion Efficiency Trend (2020–2025)
This chart illustrates how Estrella Immunopharma Inc.'s cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore Estrella Immunopharma Inc. cash debt coverage ratio to assess how comfortably operating cash covers total debt obligations.
Estrella Immunopharma Inc. Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Estrella Immunopharma Inc. ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Minehub Technologies Inc
V:MHUB
|
-1.632x |
|
DS Sigma Holdings Berhad
KLSE:0269
|
0.005x |
|
YXT.COM GROUP HOLDING LIMITED American Depository Shares
NASDAQ:YXT
|
-0.784x |
|
INIFY LABORATORIES AB
F:WY60
|
N/A |
|
Reading International Inc
NASDAQ:RDI
|
0.097x |
|
Xiabuxiabu Catering Management (China) Holdings Co. Ltd
F:0XI
|
0.589x |
|
DNA Biomed Solns
TA:DNA
|
-0.003x |
|
Qingdao Hengshun Zhongsheng
SHE:300208
|
-4.160x |
Annual Cash Flow Conversion Efficiency for Estrella Immunopharma Inc. (2020–2025)
The table below shows the annual cash flow conversion efficiency of Estrella Immunopharma Inc. from 2020 to 2025. For the full company profile with market capitalisation and key ratios, see ESLA company net worth.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $-10.37 Million | $-1.79 Million | 0.172x | +100.32% |
| 2024-12-31 | $143.73K | $-7.64 Million | -53.153x | -1313.63% |
| 2023-12-31 | $4.27 Million | $-16.07 Million | -3.760x | -2446.93% |
| 2022-12-31 | $7.07 Million | $-1.04 Million | -0.148x | -110.65% |
| 2021-12-31 | $-1.04 Million | $-1.44 Million | 1.387x | -- |
| 2020-12-31 | $0.00 | $-670.82K | x | -- |
About Estrella Immunopharma Inc.
Estrella Immunopharma, Inc., a clinical-stage biopharmaceutical company, develops T-cell therapies for blood cancers and solid tumors in the United States. The company's lead product candidate is EB103, which is in Phase I/II clinical trial, for the treatment of diffuse large B-cell lymphoma; EB104, which is in pre-clinical trial, to treat diffuse large B-cell lymphoma and acute lymphocytic leuke… Read more